RT Journal Article
T1 Prediagnostic Plasma Bile Acid Levels and Colon Cancer Risk: A Prospective Study.
A1 Kühn, Tilman
A1 Stepien, Magdalena
A1 Lopez-Nogueroles, Marina
A1 Damms-Machado, Antje
A1 Sookthai, Disorn
A1 Johnson, Theron
A1 Roca, Marta
A1 Hüsing, Anika
A1 Maldonado, Sandra González
A1 Cross, Amanda J
A1 Murphy, Neil
A1 Freisling, Heinz
A1 Rinaldi, Sabina
A1 Scalbert, Augustin
A1 Fedirko, Veronika
A1 Severi, Gianluca
A1 Boutron-Ruault, Marie-Christine
A1 Mancini, Francesca Romana
A1 Sowah, Solomon A
A1 Boeing, Heiner
A1 Jakszyn, Paula
A1 Sanchez-Perez, Maria-Jose
A1 Merino, Susana
A1 Colorado-Yohar, Sandra
A1 Barricarte, Aurelio
A1 Khaw, Kay Tee
A1 Schmidt, Julie A
A1 Perez-Cornago, Aurora
A1 Trichopoulou, Antonia
A1 Karakatsani, Anna
A1 Thriskos, Paschalis
A1 Palli, Domenico
A1 Agnoli, Claudia
A1 Tumino, Rosario
A1 Sacerdote, Carlotta
A1 Panico, Salvatore
A1 Bueno-de-Mesquita, Bas
A1 van Gils, Carla H
A1 Heath, Alicia K
A1 Gunter, Marc J
A1 Riboli, Elio
A1 Lahoz, Agustín
A1 Jenab, Mazda
A1 Kaaks, Rudolf
K1 Bile Acids and Salts
K1 Prospective Studies
K1 Taurochenodeoxycholic Acid
K1 Glycochenodeoxycholic Acid
K1 Taurodeoxycholic Acid
K1 Taurocholic Acid
K1 Glycodeoxycholic Acid
AB Bile acids have been proposed to promote colon carcinogenesis. However, there are limited prospective data on circulating bile acid levels and colon cancer risk in humans. Associations between prediagnostic plasma levels of 17 primary, secondary, and tertiary bile acid metabolites (conjugated and unconjugated) and colon cancer risk were evaluated in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Bile acid levels were quantified by tandem mass spectrometry in samples from 569 incident colon cancer cases and 569 matched controls. Multivariable logistic regression analyses were used to estimate odds ratios (ORs) for colon cancer risk across quartiles of bile acid concentrations. Positive associations were observed between colon cancer risk and plasma levels of seven conjugated bile acid metabolites: the primary bile acids glycocholic acid (ORquartile 4 vs quartile 1= 2.22, 95% confidence interval [CI] = 1.52 to 3.26), taurocholic acid (OR = 1.78, 95% CI = 1.23 to 2.58), glycochenodeoxycholic acid (OR = 1.68, 95% CI = 1.13 to 2.48), taurochenodeoxycholic acid (OR = 1.62, 95% CI = 1.11 to 2.36), and glycohyocholic acid (OR = 1.65, 95% CI = 1.13 to 2.40), and the secondary bile acids glycodeoxycholic acid (OR = 1.68, 95% CI = 1.12 to 2.54) and taurodeoxycholic acid (OR = 1.54, 95% CI = 1.02 to 2.31). By contrast, unconjugated bile acids and tertiary bile acids were not associated with risk. This prospective study showed that prediagnostic levels of certain conjugated primary and secondary bile acids were positively associated with risk of colon cancer. Our findings support experimental data to suggest that a high bile acid load is colon cancer promotive.
PB Oxford University Press
YR 2019
FD 2019-08-14
LK http://hdl.handle.net/10668/14427
UL http://hdl.handle.net/10668/14427
LA en
NO Kühn T, Stepien M, López-Nogueroles M, Damms-Machado A, Sookthai D, Johnson T, et al. Prediagnostic Plasma Bile Acid Levels and Colon Cancer Risk: A Prospective Study. J Natl Cancer Inst. 2020 May 1;112(5):516-524.
NO Bile acid measurements in the present study were funded by Helmholtz Association of German Research Centers via the project Aging and Metabolic Programming (AMPro; DKFZ). The present study was further cofinanced by the European Union through the Operational Program of the European Regional Development Fund (ERDF) of the Valencian Community 2014– 2020 (Hospital La Fe) and by the European Regional Development Fund (FEDER) Institute of Health Carlos III of the Spanish Ministry of Economy and Competitiveness (PI17/01282).The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the IARC. The national cohorts are supported by the following funders: Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Gen erale de l’Education Nationale, Institut National de la Sante et de la Recherche Medicale (INSERM), France; German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Germany; the Hellenic Health Foundation, Greece; Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council, Italy; Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands,the Netherlands; Health Research Fund (FIS, PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, PI13/02633 to EPICNavarra), Regional Governments of Andalucıa, Asturias, Basque Country, Murcia, and Navarra, ISCIII RETIC (RD06/0020), Spain; Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford), United Kingdom.
DS RISalud
RD Apr 11, 2025